One of the top issues we focus on at the Fool is understanding the quality of a company's management team. More specifically, we place a particular focus on the top dog at a company: its chief executive officer. In this video, Brenton Flynn looks at Questcor Pharmaceuticals President and CEO Don Bailey. While his reign took the company to unforeseen heights, there's been plenty of debate around how he went about it -- shrewd business or profiteering?
Questcor is one of the most debated names in all of biotech. Its premium-priced drug, Acthar, is growing at a torrid pace -- and minting money in the process. However, recent events have created significant doubts about Questcor's future. Will insurance companies continue to cover the drug? Will a government investigation lead to huge fines? We highlight these high-profile issues inside our brand new premium research report on Questcor. In it, you'll learn about the key opportunities and threats facing the company, as well as multiple reasons to buy and sell the stock. We're providing a full year of analyst updates as key news hits, so make sure to claim a copy today by clicking here now.
The article What to Make of Questcor Management originally appeared on Fool.com.Brenton Flynn has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.